Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer’s Disease

Memantine, a non-competitive NMDA receptor antagonist possessing neuroprotective properties, belongs to the small group of drugs which have been approved for the treatment of Alzheimer’s disease (AD). While several preclinical studies employing different transgenic AD mouse models have described ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Stazi, Martina, Wirths, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695672/
https://www.ncbi.nlm.nih.gov/pubmed/32914393
http://dx.doi.org/10.1007/s12035-020-02120-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695672/
https://www.ncbi.nlm.nih.gov/pubmed/32914393
http://dx.doi.org/10.1007/s12035-020-02120-z

Ejemplares similares